Skip to content

Adjunctive Mild Hypothermia Therapy to Primary Percutaneous Coronary Intervention in Patients With Acute Myocardial Infarction Complicated With Shock: A Feasibility Study

Status
UNKNOWN
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00846222
Enrollment
10
Registered
2009-02-18
Start date
2009-02-28
Completion date
2010-07-31
Last updated
2009-02-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myocardial Infarction Complicated With Cardiogenic Shock

Brief summary

The purpose of this study is evaluate the safety and feasibility of mild therapeutic hypothermia (TH) during and 12 hours after primary percutaneous coronary intervention for acute myocardial infarction complicated with shock

Interventions

PROCEDUREHypothermia

Mild therapeutic hypothermia, 33-34 celsius, for 12 hours

Sponsors

Assaf-Harofeh Medical Center
Lead SponsorOTHER_GOV

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 88 Years
Healthy volunteers
No

Inclusion criteria

* Recent myocardial infarction: 24 hours of start pain * Pump failure cardiogenic shock (defined as persistent hypotension, systolic BP \< 90 mmHg, despite fluids and catecholamines infusion, with tissue hypoperfusion signs * Candidate for immediate percutaneous reperfusion * Maximal care support: mechanical ventilation, intraaortic balloon contrapulsation

Exclusion criteria

* Cardiogenic shock related to mechanical complication: free wall rupture, acute mitral regurgitation, acute VSD, tamponade * Pregnant women * Absence of maximal support care

Design outcomes

Primary

MeasureTime frame
Primary en point: presence of major adverse cardiac events (MACE) MACE definition: death and non-fatal re-infarction.30 days

Secondary

MeasureTime frame
Infarct size calculated by area under thr curve creatinine kinase according consecutive samples Reversal stunning by blinded observer echocardiographic assessment30 days

Countries

Israel

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026